We are delighted to share that the results from our Phase 1/2 trial of BB2603 in subjects with onychomycosis (fungal nail infection) and tinea pedis (athlete’s foot) have now been published in the peer-reviewed journal, Mycoses.
BB2603 is our topical formulation of the antifungal agent terbinafine complexed with a polymer that enhances delivery through the nail and into the upper layers of the skin.
In summary:
-
BB2603 was shown to be safe and very well-tolerated, with active drug detected at the site of infection (nail) and not in circulation.
-
There was impressive anti-mycological activity seen, especially in eradication of the causative fungi.
-
BB2603 is a promising topical drug, and further trials in OM and TP are either ongoing or planned. See our clinical trials page for details of our ongoing European Phase 2 trial in onychomycosis.
For a read-only copy of the paper, click here.
We would like to thank all the patients who participated in this trial.